Cheng, H <br/><br/>
EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial.  [electronic resource] 

 -  British journal of cancer  Sep 2014 
 - 1065-71 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1532-1827 
<br/><br/><label>Standard No.: </label>10.1038/bjc.2014.442  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Biomarkers, Tumor--analysis<br/>Breast Neoplasms--chemistry<br/>Disease-Free Survival<br/>ErbB Receptors--analysis<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Middle Aged<br/>Receptor, ErbB-2--analysis<br/>Survival Rate<br/>Tissue Array Analysis<br/>Trastuzumab